Financial Results - Longevity Health Holdings, Inc. announced preliminary unaudited financial results for Q1 2025, with specific figures to be finalized later[7]. Merger Details - The company is in the process of a proposed merger with 20/20 Biolabs, Inc., with expectations of operational synergies and revenue growth post-merger[10]. - The anticipated closing of the merger is subject to stockholder approval and other conditions, with no specific date provided[10]. - The company is preparing to file relevant materials with the SEC regarding the merger, including a Form S-4 and Proxy Statement[14]. - The merger is expected to impact the ownership structure of the combined company, with adjustments to the exchange ratio possible[10]. - Management is addressing potential unknown liabilities that may arise post-merger[11]. Risks and Considerations - Risks associated with the merger include potential delays in approvals and the ability to maintain Nasdaq listing[10]. - The company emphasizes the importance of reading the SEC filings for detailed information regarding the merger[14]. - Investors are encouraged to monitor updates as the company navigates the merger process and its implications for future operations[10]. Product Development - The company is focused on launching and commercializing new products, which is expected to enhance its market position[10].
Carmell Therapeutics (CTCX) - 2025 Q1 - Quarterly Results